This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Suicidality

A Study of Nopan Treatment of Acute Suicidality

Sponsored by Prof. Yoram Yovell

About this trial

Last updated 13 years ago

Study ID

ISAN-001-09

Status

Unknown status

Type

Interventional

Phase

Phase 3

Placebo

Yes

Accepting

18-75 Years
18 to 65 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 14 years ago

What is this trial about?

Anecdotal evidence and several clinical studies found the mixed opioid agonist-antagonist Nopan to be an effective antidepressant with a rapid onset of action. It is therefore hypothesized that Nopan may be a novel and quick-acting treatment for acute suicidality. Depression, suicidality, and overall functioning will be assessed before, during and after a four-week Nopan/placebo trial. It is hypothesized that subjects who receive the active drug will show rapid improvements in objective and subjective measures of these variables.

What are the participation requirements?

Yes

Inclusion Criteria

- suicidal behavior or ideation (BSI>6)

No

Exclusion Criteria

- ECT history within the last month

- psychotic features within the last 3 months

- history of schizophrenia, substance or alcohol abuse within the last two years

- benzodiazepine dependence within the last two years

- any significant systemic illness or unstable medical condition which does not permit inclusion, according to the research physician

- pregnant women

- patients who currently suffer from severe impairment or severe dysfunction of liver, kidney, adrenal, gall, closed brain injury, urinary retention or respiratory system.